| Approved? (Admin-only) |
|
|---|---|
| Opportunity Type | Funding Opportunity Announcement (FOA) |
| Funding Opportunity Posted By | DOD |
| Component | DHA - CDMRP |
| Funding Opportunity Title | Lung Cancer Research Program |
| Opportunity ID | HT942526LCRPTRA, HT942526LCRPIDA, HT942526LCRPPCOSA |
| Link to Funding Opportunity | ebrap.org |
| Funding Opportunity Short Description | LCRP to support innovative, high-impact research with clinical relevance that will eradicate deaths and suffering from lung cancer to better the health and welfare of Service Members, Veterans and the general public. |
| Funding Opportunity Category | Health and Biomedical Technologies |
| Important Dates | |
| Open Date | 05/06/2026 |
| White Paper / Pre-Proposal / Solution Summary Due | 08/18/2026 |
| Full Applications Due | 09/02/2026 |
| Funding Details | |
| Funding Mechanism |
|
| Eligibility |
|
| Assistance Listings | 12.420 -- Military Medical Research and Development |
| Required Registrations |
|
| Funding Opportunity Full Description | The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Translational Research Award (TRA) supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Research must address at least one of the FY26 LCRP areas of emphasis. The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Idea Development Award (IDA) supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer. This mechanism promotes new ideas that are in the early stages of development and have the potential to yield impactful data and new avenues of investigation. Research must address at least one of the FY26 LCRP areas of emphasis. The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Patient-Centered Outcomes and Survivorship Award (PCOSA) promotes evidence-based and patient-centered approaches to improve health and lung cancer related outcomes and enhance the patient experience in defined populations. Research must address at least one of the FY26 LCRP areas of emphasis in the Health Outcomes and Survivorship category. |
